The Week in Review: ShangPharma Receives Go-Private Offer from Chairman  
7/9/2012 9:20:29 AM

by Richard Daverman, PhD

July 7, 2012 -- The Chairman of ShangPharma and TPG Capital have offered to take the company private at a price of between $8.50 and $9.50 per ADS; ScinoPharm, a Taiwan CMO/CRO, will spend $37.6 million to build a chemotherapy manufacturing plant in Tainan Science Park; Karl Storz, a German medical device maker, started construction of its $31.5 million China headquarters in Shanghai; Beijing is testing the zero-markup policy for hospital pharmacies at Beijing Friendship Hospital; the SEC halted trading in China Medical Technologies, a diagnostics company, pending an investigation of the companies finances. More details….

Stock Symbols: (NYSE: SHP) (TWSE: 1789) (OTCBB: CMEDY)